Accordingly, gene expression-based hierarchical and genomic studies have shown that TLX1 and TLX3 positive T-ALL share common oncogenic pathways, although they also have distinguishing features, and a different clinical outcome [5,7,52,53]. Here, TLX3 is linked to acute lymphoblastic leukemia.